Globus Medical Inc. Class A Common Stock vs Uranium Energy Corp — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Uranium Energy Corp trades at $7.58 (market cap $4.08B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 2.5× Uranium Energy Corp's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Uranium Energy Corp for 38 Days on average.
| GMED | UEC | |
|---|---|---|
Market Cap | $10.25B | $4.08B |
Volume | 1,108,124 | 14,920,249 |
Sector | Health | Energy |
52-Week High | $96.82 | $20.14 |
52-Week Low | $58.33 | $7.70 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $9.76B | $3.59B |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Uranium Energy (UEC) trades at $8.25, down 6.57% today, amid bearish technical signals despite strong analyst support. The company shows operational improvements with multi-mine expansion but faces fundamental challenges with negative net income margins (-368.62%) and declining revenue from $67M in 2025 to $37M in 2026. Recent Q4 2026 earnings beat revenue estimates but missed on EPS, while technical indicators show 18 sell signals versus 3 buy signals.
The stock presents a high-risk opportunity with Wall Street optimism (87.5% buy ratings, $16.06 consensus target) contrasting with weak financials. Key risks include unsustainable production growth, dependence on inventory sales, and cash flow challenges. Upside depends on successful execution of uranium production ramp-up and favorable government demand trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →